Status: Bibliographieeintrag
Standort: ---
Exemplare:
---
| |  Online-Ressource |
|---|
| Verfasst von: | Zhan, Tianzuo [VerfasserIn]  |
|---|
| | Rindtorff, Niklas [VerfasserIn] |
|---|
| | Betge, Johannes [VerfasserIn] |
|---|
| | Ebert, Matthias [VerfasserIn] |
|---|
| | Boutros, Michael [VerfasserIn] |
|---|
| Titel: | CRISPR/Cas9 for cancer research and therapy |
|---|
| Verf.angabe: | Tianzuo Zhan, Niklas Rindtorff, Johannes Betge, Matthias P. Ebert, Michael Boutros |
|---|
| Jahr: | 2019 |
|---|
| Jahr des Originals: | 2018 |
|---|
| Umfang: | 14 S. |
|---|
| Fussnoten: | Available online 16 April 2018 ; Gesehen am 27.05.2019 |
|---|
| Titel Quelle: | Enthalten in: Seminars in cancer biology |
|---|
| Ort Quelle: | London : Academic Press, 1995 |
|---|
| Jahr Quelle: | 2019 |
|---|
| Band/Heft Quelle: | 55(2019), Seite 106-119 |
|---|
| ISSN Quelle: | 1096-3650 |
|---|
| Abstract: | CRISPR/Cas9 has become a powerful method for making changes to the genome of many organisms. First discovered in bacteria as part of an adaptive immune system, CRISPR/Cas9 and modified versions have found a widespread use to engineer genomes and to activate or to repress the expression of genes. As such, CRISPR/Cas9 promises to accelerate cancer research by providing an efficient technology to dissect mechanisms of tumorigenesis, identify targets for drug development, and possibly arm cells for cell-based therapies. Here, we review current applications of the CRISPR/Cas9 technology for cancer research and therapy. We describe novel Cas9 variants and how they are used in functional genomics to discover novel cancer-specific vulnerabilities. Furthermore, we highlight the impact of CRISPR/Cas9 in generating organoid and mouse models of cancer. Finally, we provide an overview of the first clinical trials that apply CRISPR/Cas9 as a therapeutic approach against cancer. |
|---|
| DOI: | doi:10.1016/j.semcancer.2018.04.001 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.semcancer.2018.04.001 |
|---|
| | Volltext: http://www.sciencedirect.com/science/article/pii/S1044579X17302742 |
|---|
| | DOI: https://doi.org/10.1016/j.semcancer.2018.04.001 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Cancer |
|---|
| | Cas9 |
|---|
| | CRISPR |
|---|
| | Genome-engineering |
|---|
| | High-throughput screening |
|---|
| | Immune therapy |
|---|
| | Organoids |
|---|
| | Synthetic lethality |
|---|
| K10plus-PPN: | 166632499X |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
CRISPR/Cas9 for cancer research and therapy / Zhan, Tianzuo [VerfasserIn]; 2019 (Online-Ressource)
68393079
